Effects of etanercept and infliximab on bone metabolism indexes in patients with ankylosing spondylitis

Wang,Chenghai; Li,Weifeng

doi:10.3892/etm.2019.8266

Effects of etanercept and infliximab on bone metabolism indexes in patients with ankylosing spondylitis

Authors:
- Chenghai Wang
- Weifeng Li
View Affiliations

Affiliations: Department of Orthopaedic Surgery, The Affiliated Hospital of Hebei University of Engineering, Handan, Hebei 056000, P.R. China, Department of Orthopaedic Surgery, The First Central Hospital of Baoding, Baoding, Hebei 071000, P.R. China
Published online on: December 2, 2019 https://doi.org/10.3892/etm.2019.8266
Pages: 585-590
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Effect of etanercept and infliximab on bone metabolism indexes in patients with ankylosing spondylitis (AS) were evaluated. The clinical data of 80 patients with ankylosing spondylitis admitted to Affiliated Hospital of Hebei University of Engineering from June 2015 to March 2016 were selected. There were 39 patients treated with Enbrel as Enbrel group and 41 patients treated with Infliximab as Infliximab group. The general data of the two groups of patients were collected and various indexes before and 12 and 24 weeks after treatment were recorded. Adverse reactions of the two groups of patients after treatment were recorded and the clinical efficacy of the drugs was evaluated. C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) levels in both groups decreased significantly before and 12 and 24 weeks after treatment (P<0.05), and 24 weeks after treatment showed a downward trend compared with 12 weeks (P<0.05). The β‑collagen special sequence (β‑CTX) level in the two groups was significantly lower after treatment than before (P<0.0001). The adverse reaction rate of Infliximab group (21.95%) was higher than that of Enbrel group (5.13%) (P>0.05). The morning stiffness time, BASDAI and BASFI indexes of the two groups of patients after treatment were significantly lower than those before treatment (P<0.0001). Schober test was significantly higher than that before treatment (P<0.0001); BASDAI in Infliximab group was lower than that in etanercept group (P<0.05). Both etanercept and infliximab have good therapeutic effects on AS, which can reduce the bone metabolism level of β‑CTX in AS patients and effectively improve the symptoms of affected medullary joints. The short‑term efficacy of the two groups of patients is similar, but the incidence of adverse reactions of etanercept is slightly lower than that of infliximab.

View Figures

View References

1	Braun J and Sieper J: Ankylosing spondylitis. Lancet. 369:1379–1390. 2007. View Article : Google Scholar : PubMed/NCBI
2	Biasi D, Carletto A, Caramaschi P, Pacor ML, Maleknia T and Bambara LM: Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol. 19:114–117. 2000. View Article : Google Scholar : PubMed/NCBI
3	Quaden DH, De Winter LM and Somers V: Detection of novel diagnostic antibodies in ankylosing spondylitis: An overview. Autoimmun Rev. 15:820–832. 2016. View Article : Google Scholar : PubMed/NCBI
4	Stolwijk C, Essers I, van Tubergen A, Boonen A, Bazelier MT, De Bruin ML and de Vries F: The epidemiology of extra-articular manifestations in ankylosing spondylitis: A population-based matched cohort study. Ann Rheum Dis. 74:1373–1378. 2015. View Article : Google Scholar : PubMed/NCBI
5	Davey-Ranasinghe N and Deodhar A: Osteoporosis and vertebral fracture in ankylosing spondylitis. Curr Opin Rheumatol. 25:509–516. 2013. View Article : Google Scholar : PubMed/NCBI
6	van der Weijden MA, Claushuis TA, Nazari T, Lems WF, Dijkmans BA and van der Horst-Bruinsma IE: High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: A systematic review. Clin Rheumatol. 31:1529–1535. 2012. View Article : Google Scholar : PubMed/NCBI
7	Singh HJ, Nimarpreet K, Ashima, Das S, Kumar A and Prakash S: Study of bone mineral density in patients with ankylosing spondylitis. J Clin Diagn Res. 7:2832–2835. 2013.PubMed/NCBI
8	Smith JA: Update on ankylosing spondylitis: Current concepts in pathogenesis. Curr Allergy Asthma Rep. 15:4892015. View Article : Google Scholar : PubMed/NCBI
9	Machado MA, Moura CS, Ferré F, Bernatsky S, Rahme E and Acurcio Fde A: Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis. Rev Saude Publica. 50:502016. View Article : Google Scholar : PubMed/NCBI
10	Davis JC: Understanding the role of tumor necrosis factor inhibiton in ankylosing spondylitis. Semin Arthritis Rheum. 34:268–278. 2005. View Article : Google Scholar
11	Prince DS, McUuigan LE and McGirr EE: Working life and physical activity in ankylosing spondylit is pre and post antitumor necrosis factor-alpha therapy. Int J Rheum Dis. 17:165–172. 2014. View Article : Google Scholar : PubMed/NCBI
12	Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, Benkhalti Jandu M, Tugwell P and Wells GA: TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. Apr 18–2015.(Epub ahead of print). doi: 10.1002/14651858.CD005468.pub2. View Article : Google Scholar
13	Poddubnyy DA, Song IH and Sieper J: The safety of celecoxib in ankylosing spondylitis treatment. Expert Opin Drug Saf. 7:401–409. 2008. View Article : Google Scholar : PubMed/NCBI
14	Rauner M, Thiele S, Fert I, Araujo LM, Layh-Schmitt G, Colbert RA, Hofbauer C, Bernhardt R, Bürki A, Schwiedrzik J, et al: Loss of bone strength in HLA-B27 transgenic rats is characterized by a high bone turnover and is mainly osteoclast-driven. Bone. 75:183–191. 2015. View Article : Google Scholar : PubMed/NCBI
15	Rostom S, Dougados M and Gossec L: New tools for diagnosing spondyloarthropathy. Joint Bone Spine. 77:108–114. 2010. View Article : Google Scholar : PubMed/NCBI
16	Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Isaksson A, Pettersson K, Väänänen HK, Akesson K and Obrant KJ: Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res. 19:386–393. 2004. View Article : Google Scholar : PubMed/NCBI
17	Garnero P and Delmas PD: Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women. J Musculoskelet Neuronal Interact. 4:50–63. 2004.PubMed/NCBI
18	Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT and Delaissé JM: The type I collagen fragments ICTP and CTX reveal distinct enzymatlc pathways of bone collagen degradation. J Bone Miner Res. 18:859–867. 2003. View Article : Google Scholar : PubMed/NCBI
19	van der Linden S, Valkenburg HA and Cats A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 27:361–268. 1984. View Article : Google Scholar : PubMed/NCBI
20	Song J, Zhou L, Chen L and Wu X: Comparison of ASDAS, RAPID3 and BASDAI in assessing disease activity of patients with ankylosing spondylitis. Acad J Second Mil Med Univ. 36:909–913. 2015. View Article : Google Scholar
21	Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P and Calin A: A new approach to defining disease status in AS: The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). J Rheumatol. 21:2286–2291. 1994.PubMed/NCBI
22	Neubauer S, Cifaldi M, Mittendorf T, Ganguli A, Wolff M and Zeidler J: Biologic TNF inhibiting agents for treatment of rheumatoid arthritis persistence and dosing patterns in Germany. Health Econ Rev. 4:322014. View Article : Google Scholar : PubMed/NCBI
23	Fleischmann RM, Cohen SB, Moreland LW, Schiff M, Mease PJ, Smith DB, Keenan G and Kremer JM; iRAMT Study Group, : Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial. Curr Med Res Opin. 21:1181–1190. 2005. View Article : Google Scholar : PubMed/NCBI
24	Zhang J, Zhang YM and Zhang JL: Efficacy of etanercept in patients with ankylosing spondylitis: A double-blind, randomized, placebo controlled trial. Zhongguo Xin Yao Za Zhi. 18:1846–1849, 1881. 2009.(In Chinese).
25	Chu B, Lu MQ, Wu MQ, Shi L, Fu LN, Gao S, Fang LJ, Xiang QQ and Bao L: Clinical characteristics of bone disease in multiple myeloma and clinical significance of monitoring bone metabolic markers. Zhonghua Yi Xue Za Zhi. 96:1424–1429. 2016.(In Chinese). PubMed/NCBI
26	Fang Z, Li Y, Jiang Y and Yang F: Significance of dynamic monitoring of bone metabolites in patients with ankylosing spondylitis. Zhong Guo Yi Yuan Xie Hui. 4:447–449. 2014.(In Chinese).
27	Speden DJ, Calin AI, Ring FJ and Bhalla AK: Bone mineral density, calcaneal ultrasound, and bone turnover markers in women with ankylosing spondylitis. J Rheumatol. 29:516–521. 2002.PubMed/NCBI
28	Liu YF, Dong H, Tu SH, Zheng CH, Liu PL and Hu YH: Etanercept in the treatment of ankylosing spondylitis: A systematic review and meta-analysis. Exp Ther Med. 8:1585–1592. 2014. View Article : Google Scholar : PubMed/NCBI
29	Marakli SS, Uzun S, Ozbek S and Tuncer I: Dermatitis herpetiformis in a patient receiving infliximab for ankylosing spondylitis. Eur J Dermatol. 18:88–89. 2008.PubMed/NCBI
30	McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R and Walley T: Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess. 11:1–158. 2007. View Article : Google Scholar
31	Korczowska I, Przepiera-Bedzak H, Brzosko M, Lacki JK, Trefler J and Hrycaj P: Bone tissue metabolism in men with ankylosing spondylitis. Adv Med Sci. 56:264–269. 2011. View Article : Google Scholar : PubMed/NCBI